Active substanceMethyl ethylpyridinolMethyl ethylpyridinol Similar drugsTo uncover Cardiocipine solution d / infusion BIOSINTEZ, PAO Russia Cardiocipine solution w / m in / in BIOSINTEZ, PAO Russia Methyl ethylpyridinol solution for injections ATOLL, LLC Russia Methyl ethylpyridinol solution for injections ELLARA, LTD. Russia Methyl ethylpyridinol solution for injections Company DEKO, LLC Russia Methyl ethylpyridinol-Eskom solution for injections ESKOM NPK, OAO Russia Emoticon Optics drops d / eye SYNTHESIS, JSC Joint-stock Kurgan Society of Medical Preparations and Products Russia Emoxibel solution d / infusion Emoxibel solution for injections BELMEDPREPARATY, RUP Republic of Belarus Emoxibel drops d / eye BELMEDPREPARATY, RUP Republic of Belarus Emoxibel solution w / m in / in BELMEDPREPARATY, RUP Republic of Belarus Emoxipine® drops d / eye MOSCOW ENDOCRINE FACTORY, FSUE Russia Emoxipine solution w / m in / in MOSCOW ENDOCRINE FACTORY, FSUE Russia Emoxipine drops d / eye FARMENT FIRM, LLC Russia Emoxipine solution for injections MOSCOW ENDOCRINE FACTORY, FSUE Russia Emoxipine-AKOS drops d / eye SYNTHESIS, JSC Joint-stock Kurgan Society of Medical Preparations and Products Russia Emoxipine-Acti solution d / infusion Aktifarm, OOO Russia Dosage form: & nbspInjection. Composition:per ml: active substance: methyl ethylpyridinol hydrochloride 10 mg; Excipients: hydrochloric acid solution, 0.1 M - 0.02 ml, water for injection - up to 1 ml. Description:Transparent colorless liquid. Pharmacotherapeutic group:Antioxidant. ATX: & nbspS.01.X.A Other drugs for the treatment of eye diseases Pharmacodynamics:Angioprotector, reduces vascular wall permeability, inhibits free radical processes, antioxidant, reduces blood viscosity and platelet aggregation. Reduces the permeability of the vascular wall and the risk of developing hemorrhages, contributes to their resorption, improves the microcirculation of the eye. Has retinoprotective properties, protects the retina from the damaging effect of high-intensity light. Pharmacokinetics:The volume of distribution is 5.2 liters. Metabolised in the liver. The half-life is 18 min. Clearance - 214.8 ml / min. It is excreted by the kidneys. Indications:- subconjunctival and intraocular hemorrhages of various genesis; - angioretinopathy (including diabetic);- central and peripheral chorioretinal dystrophy;- thrombosis of the central vein of the retina and its branches;- Complicated myopathy; - angiosclerotic macular degeneration (dry form);- detachment of the vascular retina in patients with glaucoma in the postoperative period;- Dystrophic diseases of the cornea;- trauma, burns of the cornea;- Treatment and prevention of eye lesions with high intensity light (sun rays, laser radiation with laser coagulation). Contraindications:Hypersensitivity to any of the components of the drug, children under 18 years of age (efficacy and safety not established). Pregnancy and lactation:Use during pregnancy and lactation is permitted if the benefit to the mother exceeds the potential risk to the fetus and the baby. Dosing and Administration:Doses, the duration of treatment are determined individually. Subconjunctival or parabulbar, once a day or every other day. Subconjunctival - 0.2-0.5 ml of 1% solution (2-5 mg), parabulbarno -0.5-1 ml of a 1% solution (5-10 mg). Duration of treatment - 10-30 days; if necessary, it is possible to repeat the course 2-3 times a year.Retrobulbarno - 0.5-1.0 ml of 1% solution once a day for 10-15 days.To protect the retina in lacerocoagulation (incl.with limiting and destructive coagulation of tumors) - parabulbar or retrobulbarno for 0.5-1 ml of a 1% solution (5-10 mg) for 24 hours and 1 hour before coagulation; then in the same doses (0.5 ml of 1% solution) once a day for 2-10 days. Side effects:Allergic reactions: hyperemia of the skin, edema, erythema, itching, scaling of the skin;From the nervous system: short-term agitation, drowsiness;From the cardiovascular system: increased blood pressure;Other: reactions at the site of administration (pain, burning, itching, hyperemia, densification of paraorbital tissues (resolves itself). Overdose:Overdose may increase the severity of the side effects of the drug. Symptoms: increased blood pressure, agitation or drowsiness, headache, pain in the heart, nausea, discomfort in the epigastric region. There may be a clotting disorder.Treatment: withdrawal of the drug, 1 symptomatic therapy, there is no specific antidote. Interaction:Pharmaceutically incompatible with other medicines (in one syringe). The results of drug interaction with other drugs are notare described. Special instructions:Treatment should be carried out under the control of blood pressure and blood coagulability. Effect on the ability to drive transp. cf. and fur:In case of development of sleepiness, it is necessary to refrain from managing vehicles and other mechanisms, as well as from practicing potentially dangerous activities requiring rapidity of psychomotor reactions. Form release / dosage:Solution for injection 10 mg / ml. Packaging:1 ml per ampoule.For 10 ampoules, together with the instructions for use and the ampoule scarifier, are placed in a cardboard box.5 ampoules are placed in a contour mesh package.1 or 2 contour cell packstogether with the instruction for use and the ampoule scarifier are placed in a pack of cardboard. When using ampoules with a break ring, it is allowed to pack ampoules without an ampoule scarifier. Storage conditions:In the dark place at a temperature of no higher than 25 ° C.Keep out of the reach of children. Shelf life:3 years. Do not use after the expiration date printed on the package. Terms of leave from pharmacies:On prescription Registration number:П N010949 Date of registration:01.08.2011 / 05.03.2015 Expiration Date:Unlimited The owner of the registration certificate:BELMEDPREPARATY, RUP BELMEDPREPARATY, RUP Republic of Belarus Manufacturer: & nbspBELMEDPREPARATY, RUP Republic of Belarus Information update date: & nbsp2016-08-27 Illustrated instructions × Illustrated instructions Instructions